Angel Pharmaceuticals
Privately held: no public share price
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | ITKSmall molecule | Atopic DermatitisNon-Hodgkin Lymphoma Peripheral T-Cell Lymphoma | |
MupadolimabNo recent activity | Phase 1 | CD73Monoclonal antibody | Non-Small Cell Lung Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
June 2027 (1)
Est. primary completion 2027-06 · NCT07441395 · CT.gov ↗
What to watch
November 2027 (1)
soquelitinibPhase 3Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma …
Est. primary completion 2027-11 · NCT06561048 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
13 January 2025Topline resultsoquelitinibInterim Phase 1 data from Cohorts 1 and 2 in atopic dermatitis
Financial reports
No financial reports recorded.